Oliver Hartley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Oliver Hartley has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
Marianne Paolini-Bertrand
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
9 shared publicationsFabrice Cerini
Faculty of Medicine, University of Geneva, Switzerland
5 shared publicationsHubert Gaertner
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
5 shared publicationsIrène Rossitto-Borlat
Pathology and Immunology, Faculty of Medicine - University of Geneva, Switzerland
4 shared publicationsNicolas Calo
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
4 shared publicationsElsa Martins
Pathology and Immunology, Faculty of Medicine - University of Geneva, Switzerland
3 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by Universite de Geneve in Antibody Reports
- Vol. 9 (1) , e2393
ABCD_RB932 to ABCD_RB937 antibodies recognize amino acids 56 to 120 of the human cardiac troponin T isoform 6 by ELISA
ABCD_RB932, ABCD_RB933, ABCD-RB934, ABCD_RB935, ABCD_RB936 and ABCD_RB937 antibodies were generated against a peptide corresponding to amino acids 56-120 of the human cardiac troponin T isoform 6. All the discovered antibodies were able to recognize the peptide by ELISA. Antibodies ABCD_RB932, ABCD_RB934, ABCD_RB935 and ABCD_RB937 are also able to bind the full-length cardiac troponin Tand the cardiac troponin ITC complex.
- 2 February 2026
- Published by Universite de Geneve in Antibody Reports
- Vol. 9 (1) , e2393
Open AccessABCD_RB932 to ABCD_RB937 antibodies recognize amino acids 56 to 120 of the human cardiac troponin T isoform 6 by ELISA
ABCD_RB932, ABCD_RB933, ABCD-RB934, ABCD_RB935, ABCD_RB936 and ABCD_RB937 antibodies were generated against a peptide corresponding to amino acids 56-120 of the human cardiac troponin T isoform 6. All the discovered antibodies were able to recognize the peptide by ELISA. Antibodies ABCD_RB932, ABCD_RB934, ABCD_RB935 and ABCD_RB937 are also able to bind the full-length cardiac troponin Tand the cardiac troponin ITC complex.
- Open Access
- 18 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Noncanonical roles of chemokine regions in CCR9 activation revealed by structural modeling and mutational mapping
The G protein-coupled chemokine receptor CCR9 plays a major role in inflammatory bowel disease and is implicated in cancer. Despite its therapeutic relevance, the mechanism by which CCR9 is activated by its endogenous chemokine CCL25 remains poorly understood. Here, we combine structural modeling with multimodal pharmacological analysis of CCR9 mutants to map the CCR9–CCL25 interface and delineate key determinants of binding, G protein versus arrestin signaling, and constitutive activity. We show that unlike other chemokines which drive receptor activation through their N-termini, CCL25 activates CCR9 via a distinct region, its 30s loop. Supporting this non-canonical mechanism, CCR9 signaling tolerates alanine mutations in the CCL25 N-terminus but is strongly affected by 30s loop modifications. Engineered N-terminally modified CCL25 analogs remain full agonists, consistent with signaling determinants lying outside the N-terminus. This non-canonical activation signature provides insights for CCR9 drug discovery and may inform structure-based design for other chemokine receptors.
- 18 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessNoncanonical roles of chemokine regions in CCR9 activation revealed by structural modeling and mutational mapping
The G protein-coupled chemokine receptor CCR9 plays a major role in inflammatory bowel disease and is implicated in cancer. Despite its therapeutic relevance, the mechanism by which CCR9 is activated by its endogenous chemokine CCL25 remains poorly understood. Here, we combine structural modeling with multimodal pharmacological analysis of CCR9 mutants to map the CCR9–CCL25 interface and delineate key determinants of binding, G protein versus arrestin signaling, and constitutive activity. We show that unlike other chemokines which drive receptor activation through their N-termini, CCL25 activates CCR9 via a distinct region, its 30s loop. Supporting this non-canonical mechanism, CCR9 signaling tolerates alanine mutations in the CCL25 N-terminus but is strongly affected by 30s loop modifications. Engineered N-terminally modified CCL25 analogs remain full agonists, consistent with signaling determinants lying outside the N-terminus. This non-canonical activation signature provides insights for CCR9 drug discovery and may inform structure-based design for other chemokine receptors.
- Open Access
Noncanonical roles of chemokine regions in CCR9 activation revealed by structural modeling and mutational mapping
The G protein-coupled CC chemokine receptor 9 (CCR9) plays a major role in inflammatory bowel disease and has been implicated in cancer. Despite its importance as a drug target, there is limited mechanistic understanding of how CCR9 engages and is activated by its endogenous chemokine agonist CCL25. Here, by combining structural modeling with multimodal pharmacological assessment of receptor mutants, we generated a functional map of the CCR9-CCL25 interaction interface and delineated key determinants of binding, agonism, constitutive activity, and G protein vs arrestin signaling. In contrast to all complexes studied to date, where chemokines drive receptor activation through their N-termini, we determined that CCL25 activates CCR9 via a distinct region, its 30s loop. In support of this non-canonical mechanism, CCR9 signaling is tolerant to alanine mutations in the N-terminus of CCL25 but strongly affected by modifications to the 30s loop. Through molecular evolution of the CCL25 N-terminus, we identified chemokine analogs with enhanced binding properties. However, in contrast to other receptor-chemokine systems, these analogs remained full agonists, consistent with the localization of CCL25 signaling determinants outside of the N-terminus. The non-canonical signature of CCR9 activation provides new insights to aid CCR9 drug discovery and may also inform structure-based design of drugs targeting other chemokine receptors.
Open AccessNoncanonical roles of chemokine regions in CCR9 activation revealed by structural modeling and mutational mapping
The G protein-coupled CC chemokine receptor 9 (CCR9) plays a major role in inflammatory bowel disease and has been implicated in cancer. Despite its importance as a drug target, there is limited mechanistic understanding of how CCR9 engages and is activated by its endogenous chemokine agonist CCL25. Here, by combining structural modeling with multimodal pharmacological assessment of receptor mutants, we generated a functional map of the CCR9-CCL25 interaction interface and delineated key determinants of binding, agonism, constitutive activity, and G protein vs arrestin signaling. In contrast to all complexes studied to date, where chemokines drive receptor activation through their N-termini, we determined that CCL25 activates CCR9 via a distinct region, its 30s loop. In support of this non-canonical mechanism, CCR9 signaling is tolerant to alanine mutations in the N-terminus of CCL25 but strongly affected by modifications to the 30s loop. Through molecular evolution of the CCL25 N-terminus, we identified chemokine analogs with enhanced binding properties. However, in contrast to other receptor-chemokine systems, these analogs remained full agonists, consistent with the localization of CCL25 signaling determinants outside of the N-terminus. The non-canonical signature of CCR9 activation provides new insights to aid CCR9 drug discovery and may also inform structure-based design of drugs targeting other chemokine receptors.
- Open Access
- 28 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-2
Author Correction: Arylsulfatases and neuraminidases modulate engagement of CCR5 by chemokines by removing key electrostatic interactions
- 28 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-2
Open AccessAuthor Correction: Arylsulfatases and neuraminidases modulate engagement of CCR5 by chemokines by removing key electrostatic interactions
- Open Access
- 2 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Arylsulfatases and neuraminidases modulate engagement of CCR5 by chemokines by removing key electrostatic interactions
The chemokine receptor CCR5 is known to exist in cell surface subpopulations that differ in their capacity to engage ligands. One proposed explanation for this phenomenon is the presence of CCR5 species with different levels of post-translational modifications (PTMs). Tyrosine sulfation and O-glycan sialylation are PTMs that add negative charges to the extracellular domain of CCR5 and make strong contributions to chemokine binding but it is not known whether cellular mechanisms to control their levels exist. In this study we used a combination of sulfation-sensitive and sulfation-insensitive CCR5 ligands to show that the rate of turnover of CCR5 tyrosine sulfation is more rapid than the rate of turnover of the receptor itself. This suggests that the steady state level of CCR5 sulfation is maintained through the combination of tyrosine protein sulfotransferase (TPST), the trans-Golgi network (TGN)-resident ‘source enzyme, and a ‘sink’ activity that removes tyrosine sulfation from CCR5. By measuring the effects on ligand binding of knockdown and overexpression experiments, we provided evidence that non-lysosomal cellular arylsulfatases, particularly ARSG, ARSI and ARSJ, are CCR5 sulfation ‘sink’ enzymes. We also used targeted knockdown and sialylation-sensitive and insensitive chemokines to identify the sialidase NEU3 as a candidate ‘sink’ enzyme for CCR5 O-glycan sialylation. This study provides the first experimental evidence of activity of sulfatase and sialidase ‘sink’ enzymes on CCR5, providing a potential mechanism for cells to control steady-state levels of these PTMs and thereby exert dynamic control over receptor-ligand interactions at the cell surface and during receptor desensitization.
- 2 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Open AccessArylsulfatases and neuraminidases modulate engagement of CCR5 by chemokines by removing key electrostatic interactions
The chemokine receptor CCR5 is known to exist in cell surface subpopulations that differ in their capacity to engage ligands. One proposed explanation for this phenomenon is the presence of CCR5 species with different levels of post-translational modifications (PTMs). Tyrosine sulfation and O-glycan sialylation are PTMs that add negative charges to the extracellular domain of CCR5 and make strong contributions to chemokine binding but it is not known whether cellular mechanisms to control their levels exist. In this study we used a combination of sulfation-sensitive and sulfation-insensitive CCR5 ligands to show that the rate of turnover of CCR5 tyrosine sulfation is more rapid than the rate of turnover of the receptor itself. This suggests that the steady state level of CCR5 sulfation is maintained through the combination of tyrosine protein sulfotransferase (TPST), the trans-Golgi network (TGN)-resident ‘source enzyme, and a ‘sink’ activity that removes tyrosine sulfation from CCR5. By measuring the effects on ligand binding of knockdown and overexpression experiments, we provided evidence that non-lysosomal cellular arylsulfatases, particularly ARSG, ARSI and ARSJ, are CCR5 sulfation ‘sink’ enzymes. We also used targeted knockdown and sialylation-sensitive and insensitive chemokines to identify the sialidase NEU3 as a candidate ‘sink’ enzyme for CCR5 O-glycan sialylation. This study provides the first experimental evidence of activity of sulfatase and sialidase ‘sink’ enzymes on CCR5, providing a potential mechanism for cells to control steady-state levels of these PTMs and thereby exert dynamic control over receptor-ligand interactions at the cell surface and during receptor desensitization.
- Open Access
- 17 October 2023
- Published by Springer Nature in Research Square
Arylsulfatases and neuraminidases modulate engagement of CCR5 by chemokines by removing key electrostatic interactions
The chemokine receptor CCR5 is known to exist in cell surface subpopulations that differ in their capacity to engage ligands. One proposed explanation for this phenomenon is the presence of CCR5 species with different levels of post-translational modifications (PTMs). Tyrosine sulfation and O-glycan sialylation are PTMs that add negative charges to the extracellular domain of CCR5 and make strong contributions to chemokine binding but it is not known whether cellular mechanisms to control their levels exist. In this study we used a combination of sulfation-sensitive and sulfation-insensitive CCR5 ligands to show that the rate of turnover of CCR5 tyrosine sulfation is more rapid than the rate of turnover of the receptor itself. This suggests that the steady state level of CCR5 sulfation is maintained through the combination of tyrosine protein sulfotransferase (TPST), the trans-Golgi network (TGN)-resident ‘source enzyme, and a ‘sink’ activity that removes tyrosine sulfation from CCR5. By measuring the effects on ligand binding of knockdown and overexpression experiments, we provided evidence that non-lysosomal cellular arylsulfatases, particularly ARSG, ARSI and ARSJ, are CCR5 sulfation ‘sink’ enzymes. We also used targeted knockdown and sialylation-sensitive and insensitive chemokines to identify the sialidase NEU3 as a candidate ‘sink’ enzyme for CCR5 O-glycan sialylation. This study provides the first experimental evidence of activity of sulfatase and sialidase ‘sink’ enzymes on CCR5, providing a potential mechanism for cells to control steady-state levels of these PTMs and thereby exert dynamic control over receptor-ligand interactions at the cell surface and during receptor desensitization.
- 17 October 2023
- Published by Springer Nature in Research Square
Open AccessArylsulfatases and neuraminidases modulate engagement of CCR5 by chemokines by removing key electrostatic interactions
The chemokine receptor CCR5 is known to exist in cell surface subpopulations that differ in their capacity to engage ligands. One proposed explanation for this phenomenon is the presence of CCR5 species with different levels of post-translational modifications (PTMs). Tyrosine sulfation and O-glycan sialylation are PTMs that add negative charges to the extracellular domain of CCR5 and make strong contributions to chemokine binding but it is not known whether cellular mechanisms to control their levels exist. In this study we used a combination of sulfation-sensitive and sulfation-insensitive CCR5 ligands to show that the rate of turnover of CCR5 tyrosine sulfation is more rapid than the rate of turnover of the receptor itself. This suggests that the steady state level of CCR5 sulfation is maintained through the combination of tyrosine protein sulfotransferase (TPST), the trans-Golgi network (TGN)-resident ‘source enzyme, and a ‘sink’ activity that removes tyrosine sulfation from CCR5. By measuring the effects on ligand binding of knockdown and overexpression experiments, we provided evidence that non-lysosomal cellular arylsulfatases, particularly ARSG, ARSI and ARSJ, are CCR5 sulfation ‘sink’ enzymes. We also used targeted knockdown and sialylation-sensitive and insensitive chemokines to identify the sialidase NEU3 as a candidate ‘sink’ enzyme for CCR5 O-glycan sialylation. This study provides the first experimental evidence of activity of sulfatase and sialidase ‘sink’ enzymes on CCR5, providing a potential mechanism for cells to control steady-state levels of these PTMs and thereby exert dynamic control over receptor-ligand interactions at the cell surface and during receptor desensitization.
- Open Access
- 18 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (25) , eabg8685
Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist
The structure of CCR5 in complex with [6P4]CCL5 and the G i protein reveals its activation mechanism.
- 18 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (25) , eabg8685
Open AccessStructural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist
The structure of CCR5 in complex with [6P4]CCL5 and the G i protein reveals its activation mechanism.
- Open Access
- 1 June 2021
- Published by Swiss Chemical Society in Chimia
- Vol. 75 (6) , 489-494
Precision-engineered Peptide and Protein Analogs: Establishing a New Discovery Platform for Potent GPCR Modulators
Numerous members of the human G protein-coupled receptor (GPCR) superfamily are receptors of therapeutic interest. GPCRs are considered to be highly tractable for drug discovery, representing the targets of approximately one-third of currently licensed drugs. These successful drug discovery outcomes cover only a relatively small subset of the superfamily, however, and many other attractive receptors have proven to present significant challenges. Among these difficult GPCRs are those whose natural ligands are peptides and proteins. In this review we explain the obstacles faced by GPCR drug discovery campaigns, with particular focus on those related to peptide and protein GPCRs. We describe a novel and promising approach for these targets based on engineering of their natural ligands and describe an integrated discovery platform that allows potent ligand analogs to be discovered rapidly and efficiently. Finally, we present a case study involving the chemokine receptor CCR5 to show that this approach can be used to generate new drugs for peptide and protein GPCR targets combining best-in-class potency with tunable signaling activity.
- 1 June 2021
- Published by Swiss Chemical Society in Chimia
- Vol. 75 (6) , 489-494
Open AccessPrecision-engineered Peptide and Protein Analogs: Establishing a New Discovery Platform for Potent GPCR Modulators
Numerous members of the human G protein-coupled receptor (GPCR) superfamily are receptors of therapeutic interest. GPCRs are considered to be highly tractable for drug discovery, representing the targets of approximately one-third of currently licensed drugs. These successful drug discovery outcomes cover only a relatively small subset of the superfamily, however, and many other attractive receptors have proven to present significant challenges. Among these difficult GPCRs are those whose natural ligands are peptides and proteins. In this review we explain the obstacles faced by GPCR drug discovery campaigns, with particular focus on those related to peptide and protein GPCRs. We describe a novel and promising approach for these targets based on engineering of their natural ligands and describe an integrated discovery platform that allows potent ligand analogs to be discovered rapidly and efficiently. Finally, we present a case study involving the chemokine receptor CCR5 to show that this approach can be used to generate new drugs for peptide and protein GPCR targets combining best-in-class potency with tunable signaling activity.
- 1 June 2021
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 37 (6) , 453-460
Evaluation of the Safety, Acceptability, and Pharmacokinetic Profile of a Gel Formulation of OB-002 in Healthy Volunteers
OB-002 is an extremely potent CCR5 antagonist that has previously been shown to completely block transmission in a nonhuman primate model of HIV infection. The purpose of this study was to characterize the safety, acceptability, and pharmacokinetic profile of a gel formulation of OB-002 (OB-002H). The trial had two phases, an open label single dose exposure (vaginal and rectal) and a randomized placebo controlled multiple dose phase during which study participants received five vaginal daily doses of OB-002H gel or matched placebo in a 2:1 ratio. Serum OB-002 levels were quantified at multiple time points up to 24 h after the first dose. A total of thirty female and male participants were enrolled in the study (12 in the single dose phase and 18 in the multiple dose phase). All adverse events were Grade 1 or 2, and the majority was unrelated to study product. Only two product-related transient Grade 2 events (both vulval dryness) occurred in the study, both in the OB-002H gel randomized multiple dose arm. All colposcopic and anoscopic assessments following product exposure were normal. There was no evidence of systemic absorption of OB-002. Overall, the product had a positive acceptability profile, and most study participants would consider using the product for protection against HIV or pregnancy. Future studies are needed to assess the extended safety and acceptability of OB-002H gel in sexually active participants. Clinical Trial Registration Number: NCT04791007
- 1 June 2021
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 37 (6) , 453-460
Evaluation of the Safety, Acceptability, and Pharmacokinetic Profile of a Gel Formulation of OB-002 in Healthy Volunteers
OB-002 is an extremely potent CCR5 antagonist that has previously been shown to completely block transmission in a nonhuman primate model of HIV infection. The purpose of this study was to characterize the safety, acceptability, and pharmacokinetic profile of a gel formulation of OB-002 (OB-002H). The trial had two phases, an open label single dose exposure (vaginal and rectal) and a randomized placebo controlled multiple dose phase during which study participants received five vaginal daily doses of OB-002H gel or matched placebo in a 2:1 ratio. Serum OB-002 levels were quantified at multiple time points up to 24 h after the first dose. A total of thirty female and male participants were enrolled in the study (12 in the single dose phase and 18 in the multiple dose phase). All adverse events were Grade 1 or 2, and the majority was unrelated to study product. Only two product-related transient Grade 2 events (both vulval dryness) occurred in the study, both in the OB-002H gel randomized multiple dose arm. All colposcopic and anoscopic assessments following product exposure were normal. There was no evidence of systemic absorption of OB-002. Overall, the product had a positive acceptability profile, and most study participants would consider using the product for protection against HIV or pregnancy. Future studies are needed to assess the extended safety and acceptability of OB-002H gel in sexually active participants. Clinical Trial Registration Number: NCT04791007
- Open Access
- 1 January 2021
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1865 (1) , 129753
CCR5 tyrosine sulfation heterogeneity generates cell surface receptor subpopulations with different ligand binding properties
- 1 January 2021
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1865 (1) , 129753
Open AccessCCR5 tyrosine sulfation heterogeneity generates cell surface receptor subpopulations with different ligand binding properties